Table 1.
Patient characteristics at time of switching
| All enrolled patients | Patients in DCR analysis | Excluded from DCR analysis | |
|---|---|---|---|
| N | 302 | 206 | 96 |
| Patient demographics | |||
| Age (years), mean (SD) | 65 (15) | 62 (15) | 65 (15.5) |
| Gender, male, n (%) | 184 (61) | 127 (62) | 57 (59) |
| Clinical characteristics | |||
| Prior history, n (%) | |||
| Diabetes | 105 (35) | 67 (32) | 38 (40) |
| Cardiovascular disease | 199 (66) | 139 (67) | 60 (62) |
| Primary etiology of kidney disease, n (%) | |||
| Diabetes | 70 (23) | 44 (21) | 26 (27) |
| Glomerular nephropathy | 44 (15) | 38 (18) | 6 (6) |
| Hypertension | 39 (13) | 28 (14) | 11 (12) |
| Interstitial nephropathy | 30 (10) | 18 (9) | 12 (13) |
| Polycystic kidney disease | 14 (5) | 12 (6) | 2 (2) |
| Other/unknown | 105 (34) | 66 (32) | 39 (40) |
| Duration of dialysis (months), median (Q1, Q3) | 42 (24, 73) | 42 (25, 72) | 42 (23, 78) |
| Darbepoetin alfa dose frequency, n (%) | |||
| QW | 192 (64) | 122 (60) | 70 (73) |
| Q2W | 67 (22) | 44 (21) | 23 (24) |
| >Q2W | 43 (14) | 40 (19) | 3 (3) |
| Duration of darbepoetin alfa treatment (months), median (Q1, Q3) | 28 (16, 39) | 25 (15, 37) | 31 (22, 49) |
| Mean weekly darbepoetin alfa dose (μg), geometric mean (95% CI) | 27.7 (25.1, 30.5) | 24.1 (21.3, 27.1) | 37.7 (32.5, 43.6) |
| Hb (g/dL), mean (SD) | 11.5 (1.1) | 11.5 (1.1) | 11.6 (1.3) |
CI confidence interval, DCR dose conversion ratio, Hb hemoglobin, Q1, Q3 interquartile range, Q2W every 2 weeks, QW once weekly